ClinicaliQ Trial Snapshot
- GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT06620185.
- What is being tested: This study compares mucosal immune responses in the upper and lower respiratory tract following nasal-spray live-attenuated influenza vaccine (LAIV) versus standard vaccination, examining how effectively each route generates local immunity in lung and lymphoid tissue.
- Patient eligibility overview: Healthy adult volunteers aged 18-55 years without significant respiratory disease, immunosuppression, or contraindications to influenza vaccination are eligible; the study excludes those with chronic lung conditions or immunocompromised status.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a live-attenuated influenza vaccine delivered by nasal spray versus influenza A (H3N2) viral challenge.
Eligibility Snapshot
- : * Adults aged between 18-55 years inclusive * Sero-suitable as defined by a serum micro-neutralisation titre
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.